Oral iron chelation

Same author

Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.

FEBS letters·1998

Same author

New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.

Annals of the New York Academy of Sciences·1998

Same author

Iron chelation therapy: the need for orally active drugs.

The Journal of laboratory and clinical medicine·1998

Same author

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.

Oncogene·1998

Same author

Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukaemia: an update of recent scientific reports.

British journal of haematology·1998

Same author

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

Blood·1998

Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026

Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026

Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026

Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026

Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026

Same journal

Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.

Seminars in hematology·2026

Related Experiment Videos

Oral iron chelation

Related Concept Videos

Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.

New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.

Iron chelation therapy: the need for orally active drugs.

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.

Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukaemia: an update of recent scientific reports.

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

The many facets of cardiopulmonary complications in sickle cell disease.

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Telomeres biology disorders: the past, the present and the future.

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.

Related Experiment Videos

Oral iron chelation

Related Concept Videos

Related Articles

Okadaic acid-induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl-2 mRNA and downregulation of bcl-2 protein.

New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia.

Iron chelation therapy: the need for orally active drugs.

Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr/abl-positive leukaemia cells.

Lack of clonal BCRA2 gene deletion on chromosome 13 in chronic lymphocytic leukaemia: an update of recent scientific reports.

Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.

The many facets of cardiopulmonary complications in sickle cell disease.

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Telomeres biology disorders: the past, the present and the future.

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Evolving insights into mitochondrial presence in RBC in sickle cell disease: Red blood cell and reticulocyte pathophysiology, therapeutic strategies, and future directions.